NCT01148225View on ClinicalTrials.gov

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

PHASE3CompletedINTERVENTIONAL
Enrollment

424

Participants

Timeline

Start Date

November 23, 2010

Primary Completion Date

May 21, 2018

Study Completion Date

May 21, 2018

Conditions
Uveitis
Interventions
DRUG

adalimumab

Adalimumab, pre-filled syringe, administered by SC injection

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY